Cmg Pharmaceutical Co., Ltd.

Sungkwang Medical Foundation

Ju Hui Jeong

Jin Sung Kim

Chan Su Kim

Hye Sun Jeon

Hyun Sook An

Soojeong Kim

Young Eun Kwon

Na Keum Lee

Young Sang Kim

Hong Jae Jeon

Sungmoo Kim

Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: in which R, R, R, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER, and/or c-Met is inhibited, the compound or pharmaceutically acceptable salt thereof can re-sensitize cancer cells, such as non-small cell lung cancer cells, that have grown resistant to an anti-cancer agent.

Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof

Provided is an inhibitor of an indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) of formula (I) or a pharmaceutically acceptable salt thereof: in which W, W, W, and W, X, Y, Z, Z, and Rare described herein. Further provided is a method of treating or preventing a IDO and/or TDO-mediated disease using an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

IDO-TDO dual inhibitor and related methods of use

Growing community of inventors

Seongnam, South Korea

Ju Hui Jeong